GlassScriptPhysician profile
Deborah Di Stefano
NPI 1932172558
$5,944.52
in general payments reported to CMS, 2019-2025
25 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $628 · 2021: $649 · 2022: $1,603 · 2023: $938 · 2024: $892 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,360 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.41 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,487.76 | 2019-2025 | Cequa, Ilumya |
| Mallinckrodt Hospital Products INC. | $1,028.02 | 2020-2025 | Acthar |
| Abbvie INC. | $593.15 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Allergan, INC. | $462.56 | 2019-2022 | |
| Merz North America, INC. | $334.14 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $325.61 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Novartis Pharmaceuticals Corporation | $321.91 | 2019-2023 | |
| Revance Therapeutics, INC. | $280.19 | 2024-2025 | Daxxify, Daxi |
| Tarsus Pharmaceuticals, INC. | $171.53 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $143.10 | 2019-2025 | Tryptyr, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $115.87 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $111.74 | 2019 | |
| Oyster Point Pharma, INC. | $95.74 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $65.22 | 2019-2021 | |
| Harrow Eye, LLC | $64.57 | 2024 | Vevye |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $58.22 | 2019 | |
| Galderma Laboratories, L.P. | $53.34 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $49.82 | 2022-2023 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $46.75 | 2019-2020 | |
| Dompe US, INC. | $44.94 | 2024-2025 | Oxervate |
| Biotissue Holdings INC. | $20.64 | 2019 | |
| Alcon Research LLC | $19.42 | 2019 | |
| Omeros Corporation | $17.39 | 2019 | |
| Ocular Therapeutix, INC. | $16.50 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Di Stefano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.